Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism
Status:
Completed
Trial end date:
2019-02-24
Target enrollment:
Participant gender:
Summary
A Randomized, active comparator, two-part, partial crossover design. The study is designed to
assess the pharmacokinetics and pharmacodynamics of EnteraBio's Oral PTH(1-34) [EB612
(EBP05)] in adult patients with hypoparathyroidism.